Regulation under the PMD Act, Health Insurance and Drug Pricing Systems
First written in FY2017. 2 of 3 entries say "Restated". Latest entry: FY2019.
The whole theme swung hardest in 2018: 19 of 65 companies on the "Worse" side.
48 other companies' latest entry also says "Restated".
- FY2019RestatedAnnual report
「The Group’s business is affected by regulations in Japan, including the Pharmaceuticals and Medical Devices Act, the health insurance system and the drug pricing system, as well as various related regulations in overseas countries.」
The risk that pharmaceutical regulations in Japan and overseas could affect operating performance and financial condition continues to be disclosed. - FY2018RestatedAnnual report
「The Group’s business is affected by regulations in Japan, including the Pharmaceuticals and Medical Devices Act, the health insurance system and the drug pricing system, as well as various related regulations in overseas countries.」
The risk that pharmaceutical regulations in Japan and overseas could affect operating performance and financial condition continues to be disclosed. - FY2017First statedAnnual report
「The Group’s business is affected by regulations in Japan, including the Pharmaceuticals and Medical Devices Act, the health insurance system and the drug pricing system, as well as various related regulations in overseas countries.」
The Group identifies the risk that domestic and overseas pharmaceutical regulations and unforeseeable changes in healthcare policy could affect business results and financial condition.